Exact Sciences Corporation (EXAS): Price and Financial Metrics

Exact Sciences Corporation (EXAS)

Today's Latest Price: $138.59 USD

2.45 (-1.74%)

Updated Jan 27 1:47pm

Add EXAS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

EXAS Stock Summary

  • With a market capitalization of $21,215,805,896, Exact Sciences Corp has a greater market value than 89.75% of US stocks.
  • Over the past twelve months, EXAS has reported earnings growth of 179.92%, putting it ahead of 92.18% of US stocks in our set.
  • As for revenue growth, note that EXAS's revenue has grown 82.48% over the past 12 months; that beats the revenue growth of 93.53% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Exact Sciences Corp are AKAM, WST, LOGI, HZNP, and CHKP.
  • Visit EXAS's SEC page to see the company's official filings. To visit the company's web site, go to www.exactsciences.com.

EXAS Stock Price Chart Interactive Chart >

Price chart for EXAS

EXAS Price/Volume Stats

Current price $138.59 52-week high $159.54
Prev. close $141.04 52-week low $35.25
Day low $131.74 Volume 1,552,989
Day high $140.06 Avg. volume 1,943,107
50-day MA $132.56 Dividend yield N/A
200-day MA $101.05 Market Cap 20.85B

Exact Sciences Corporation (EXAS) Company Bio

Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin.

EXAS Latest News Stream

Event/Time News Detail
Loading, please wait...

EXAS Latest Social Stream

Loading social stream, please wait...

View Full EXAS Social Stream

Latest EXAS News From Around the Web

Below are the latest news stories about Exact Sciences Corp that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

Apogee Enterprises, Inc. (NASDAQ:APOG) Passed Our Checks, And It's About To Pay A US$0.20 Dividend

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Yahoo | January 25, 2021

Exact Sciences: Patching The Acquisitions Together

The current cancer treatments lack efficiency, and late diagnostics make everything harder. As a matter of fact, experts have been telling us for a long time that early detection is fundamental to have a significant increase in survival rates. The holy grail for early cancer detections could be a blood...

Nelson Alves on Seeking Alpha | January 21, 2021

Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp. By Investing.com

Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp.

Investing.com | January 21, 2021

Cologuard accurately screens younger individuals for colorectal cancer

The U.S. Preventive Services Task Force (USPSTF) appears on the verge of expanding colorectal cancer screening to individuals ages 45 to 49, based on its latest draft recommendations. If it does, Exact Sciences Corp. is ready. A study in Cancer Prevention Research demonstrated that the Madison, Wis.-based company's Cologuard multitarget stool DNA test had better than 95% specificity in individuals with nonadvanced precancerous lesions or negative findings on colonoscopy.

BioWorld | January 15, 2021

15 Best Undervalued Stocks to Buy Now

In this article, we present to you the 15 Best Undervalued Stocks to Buy Now. If you’re in a hurry, click to skip ahead and jump to the 5 Best Undervalued Stocks to Buy Now. Investing in the stock market could be difficult. We can classify investors based on their portfolios. The low risk-takers who […]

Yahoo | January 14, 2021

Read More 'EXAS' Stories Here

EXAS Price Returns

1-mo 2.08%
3-mo 15.01%
6-mo 46.27%
1-year 52.78%
3-year 176.79%
5-year 2,009.44%
YTD 4.60%
2020 43.26%
2019 46.56%
2018 20.10%
2017 293.26%
2016 44.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9037 seconds.